Latest Content

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Nearly 72% of patients hospitalized for heart failure had 2 or more other CKM conditions, with the strongest links to poor outcomes in HFrEF.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

Among nearly 48 million US adults eligible for obesity medications, oral semaglutide initiation climbed quickly after its December 2025 FDA approval.